Investor deck highlights TONMYA launch and pipeline updates
Tonix highlighted commercial traction for fibromyalgia drug TONMYA, launched Nov. 17, 2025; first FDA-approved adult fibromyalgia treatment in 15+ years.
Reported 1Q’26 net sales of $3.7 million; $5.1 million from Nov. 17, 2025 to Mar. 31, 2026.
Disclosed ~$185.5 million cash and cash equivalents as of March 31, 2026; no debt; runway expected into early Q2’27.
Pipeline update included TNX-4800 Lyme disease prevention adaptive Phase 2 field study planned for 1H’27 in the U.S.
Other planned studies: TNX-1500 organ transplant rejection Phase 2 in 2H’26; TNX-2900 Prader-Willi syndrome Phase 2 in 1Q’27.
TNXP•
